Does eculizumab have the same efficacy in MOG-positive NMOSD as in AQP4-positive NMOSD?

Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... Sep 29, 2023 ... What are the side effects of Soliris? · headache · diarrhea · high blood pressure (hypertension) · common cold (upper respiratory infection ) ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study This outcome appears to be changing in recent years with the development of eculizumab (Soliris, Alexion Phar- maceuticals, Inc), an antibody inhibitor of ... Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Dec 12, 2022 ... It may be given to your child for other reasons. Talk with the doctor. Eculizumab. 2/11. Page 3 ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data.